-
Mashup Score: 0Ocaliva plus bezafibrate clears FDA orphan drug hurdle for primary biliary cholangitis - 11 month(s) ago
The FDA granted Intercept Pharmaceuticals orphan drug designation for the fixed-dose combination of obeticholic acid and bezafibrate intended for treatment of patients with primary biliary cholangitis. Obeticholic acid (Ocaliva, Intercept Pharmaceuticals) — a farnesoid X receptor agonist — was originally FDA approved for primary biliary cholangitis (PBC) in 2016 in combination with
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Combo Tx Upped Transplant-Free Survival in Japanese PBC Patients - 4 year(s) ago
Adding bezafibrate to UDCA showed promise in large retrospective analysis
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
ICYMI: "Japanese clinicians and researchers were the first to combine UDCA with #bezafibrate treatment in patients who did not respond adequately to #UDCA alone." @AmerGastroAssn #ILC2020 #AGAConfRep https://t.co/ee5aKSRmpY
-
-
Mashup Score: 0Bezafibrate after UDCA improves survival in PBC - 4 year(s) ago
Patients with primary biliary cholangitis who received bezafibrate after incomplete response to Ocaliva showed lower risk for death or liver transplant, according to a presenter at the Digital International Liver Congress.“Ursodeoxycholic acid [Ocaliva, Intercept] is a first-line treatment for primary biliary cholangitis. As you know, 20% to 30% of patients exhibit incomplete response to
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ILC2020: Nationwide cohort in Japan shows #bezafibrate benefits #PBC as a second-line treatment after #UDCA https://t.co/bB0pwn2IEK
-
#ICYMI: #Ocaliva plus #bezafibrate clears @US_FDA orphan #drug hurdle for primary biliary #cholangitis @InterceptPharma #GITwitter #MedTwitter https://t.co/iPpEK8qmuG